PMID- 22998641
OWN - NLM
STAT- MEDLINE
DCOM- 20130425
LR  - 20131106
IS  - 1746-045X (Electronic)
IS  - 1746-0441 (Linking)
VI  - 7
IP  - 12
DP  - 2012 Dec
TI  - Novel treatment avenues for peripheral T-cell lymphomas.
PG  - 1149-63
LID - 10.1517/17460441.2012.727392 [doi]
AB  - INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) and natural killer (NK) or 
      T-cell non-Hodgkin's lymphomas (NHLs) are a rare and heterogeneous class of 
      diseases with generally poor prognosis. This work intends to provide a focused 
      primer on clinical diagnosis, current treatment regimens, and novel therapeutic 
      approaches. The recent WHO classification has defined 18 different subtypes of 
      PTCL and NK T-cell lymphomas. Diagnosis is mainly based on histology, 
      flow-cytometric analysis of surface molecules in the blood and bone marrow, 
      cytogenetics/fluorescence in situ hybridization (FISH), and T-cell receptor (TCR) 
      rearrangement. Staging as well as follow-up diagnostic procedures rely on imaging 
      techniques such as computerized tomography (CT) and positron emission tomography 
      (PET). Current chemotherapeutic regimens such as CHOP result in a 60 - 70% 
      response rate; however, 5-year survival is only around 30%. Therefore, new 
      treatment strategies are urgently needed. Currently, different drug classes are 
      under scrutiny. AREAS COVERED: The authors discuss substances that directly 
      target the tumor cells. The article includes such substances as antimetabolites, 
      antibodies, histone deacetylase inhibitors, tyrosine kinase inhibitors, and 
      immunomodulatory substances such as lenalidomide. EXPERT OPINION: In the future a 
      close collaboration of geneticists, biochemists, and clinicians together with new 
      technologies such as deep sequencing will allow the refinement of treatment 
      strategies in many diseases including PTCLs and NHLs. This refinement will allow 
      treatments to be prepared according to the need of the individual patient.
FAU - Hopfinger, Georg
AU  - Hopfinger G
AD  - 3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, 
      Rheumatology and Infectiology of the Paracelsus Private Medical University, 
      Laboratory for Immunological and Molecular Cancer Research, Mullner Hauptstrasse 
      48, 5020 Salzburg, Austria. g.hopfinger@salk.at
FAU - Griessl, Robert
AU  - Griessl R
FAU - Sifft, Eveline
AU  - Sifft E
FAU - Taylor, Ninon
AU  - Taylor N
FAU - Kenner, Lukas
AU  - Kenner L
FAU - Greil, Richard
AU  - Greil R
FAU - Merkel, Olaf
AU  - Merkel O
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20120924
PL  - England
TA  - Expert Opin Drug Discov
JT  - Expert opinion on drug discovery
JID - 101295755
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Drug Discovery
MH  - Flow Cytometry/methods
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Killer Cells, Natural/classification
MH  - Lymphoma, T-Cell, Peripheral/classification/*drug therapy
EDAT- 2012/09/25 06:00
MHDA- 2013/04/26 06:00
CRDT- 2012/09/25 06:00
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2013/04/26 06:00 [medline]
AID - 10.1517/17460441.2012.727392 [doi]
PST - ppublish
SO  - Expert Opin Drug Discov. 2012 Dec;7(12):1149-63. doi: 
      10.1517/17460441.2012.727392. Epub 2012 Sep 24.